Empirical antibacterial treatment for sepsis and the role of glycopeptides: Recommendations from a European panel

Clinical Microbiology and Infection

Volumn 3, Issue 3, 1997, Pages 273-282

  Pittet, Didier ^a,i   Menichetti, Francesco ^b   Antunes, Francisco ^c   Garau, Javier ^d   Graninger, Wolfgang ^e   Grüneberg, Reuben N ^f   Peetermans, Willy E ^g   Shah, Pramod M ^h  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b Servizio di Radioterapia Oncologica   (Italy)

^c HOSPITAL DE SANTA MARIA   (Portugal)

^d HOSPITAL MÚTUA DE TERRASSA   (Spain)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h GOETHE UNIVERSITY   (Germany)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Antibiotics; Bacteremia; Glycopeptides; Sepsis; Treatment proposals

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; GENTAMICIN; METRONIDAZOLE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM;

BACTEREMIA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SEPSIS;

EID: 0030744448     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1997.tb00614.x     Document Type: Review

References (69)

1. Bone RC, Fisher CJ Jr. Clemmer TP, Slotman GJ, Metz CA, Balk RA. Sepsis syndrome: a valid clinical entity. Methyl-prednisolone severe sepsis study group. Crit Care Med 1989; 17(5): 389-93.
2. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20(6): 864-74.
3. Centers for Diseases Control. Increase in national hospital discharge survey rates for septicaemia - United States 1979-1987. MMWR 1990; 39: 31-4.
4. Banerjee SN, Emori TG, Culver DH et al. Secular trends in nosocomial bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991; 91(3B): 86S-9S.
5. Pittet D, Wenzel RP. Nosocomial bloodstream infections: secular trends in rates, mortality and contribution to total hospital deaths. Arch Intern Med 1995; 155: 1177-84.
6. Morrison AJ Jr, Freer CV, Searcy MA, Landry SM, Wenzel RP. Nosocomial bloodstream infections: secular trends in a statewide program in Virginia. Infect Control 1986; 7. 550-3
7. Shah P, Rousselet W, Stille W. Septicaemia at the Department of Internal Medicine of a University Hospital 1986-1988. In Adam D, Lode H, Rubinstein E, eds. Recent advances in chemotherapy. Proceedings of the 17th International Congress of Chemotherapy, Berlin Munich: Futuramed Publishers, 1991: 1942-3.
8. Haug JB, Harthug S, Kalager T, Digranes A, Solberg CO. Septicaemia at a Norwegian University Hospital 1974-79 (5 years) and 1988-89 (2 years). A comparative study. In Adam D, Lode H, Rubinstein E, eds. Recent advances in chemotherapy. Proceedings of the 17th International Congress of Chemotherapy, Berlin. Munich: Futuramed Publishers, 1991: 1944-5.
9. Centers for Disease Control and Prevention. Annual summary of births, marriages, divorces and deaths: United States, 1993. Monthly Vital Statistics Rep 1994; 42: 4-10.
10. Pittet D. Nosocomial bloodstream infections. In Wenzel RP, ed. Prevention and control of nosocomial infections, 2nd edn. Baltimore: Williams and Wilkins, 1993: 512-55.
11. Eykyn SJ, Gransden WR, Phillips I. The causative organisms of septicaemia and their epidemiology. J Anumicrob Chemother 1990: 25(suppl C): 41-58.
12. Rosenthal EJK. Septikämie-erreger 1983-1985. Dtsch Med Wochenschr 1986; 111: 1874-80.
13. Rosenthal EJK. Epidemiologie von septikàmie-erregern. Blurkulturstudie der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. Dtsch Med Wochenschr. 1993; 118: 1269-75.
14. Dornbusch K, the European Study Group on Antibiotic Resistance. Resistance to betalactam antibiotics and ciprofloxacin in Gram-negative bacilli and staphylococci isolated from blood: a European collaborative study. J Antimicrob Chemother 1990; 26: 269-78.
15. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methyl-prednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317(11): 653-8.
16. Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987; 317(11): 659-65.
17. Greenman RL, Schein RM, Martin MA et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991; 266(8): 1097-102.
18. Brun-Buisson C, Doyon F, Carlet J, the French ICU Group for Severe Sepsis. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults A multicenter prospective study in intensive care units. JAMA 1995; 274: 968-74.
19. Pittet D, Thievent B, Wenzel RP, Li N, Auckenthaler R, Suter PM. Bedside prediction of mortality from bacteremic sepsis: a dynamic analysis of ICU patients. AmJ Pulm Crit Care Med 1996; 153: 684-93.
20. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271: 1598-601.
21. Bryan CS, Reynolds KL, Brenner ER. Analysis of 1186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 1983; 5: 629-38.
22. Filice GA, Van Etta LL, Darby CP, Fraser DW. Bacteremia in Charleston County, South Carolina. Am J Epidemiol 1986; 123: 128-36.
23. Roberts FJ, Geere IW, Coldman A. A three-year study of positive blood cultures with emphasis on prognosis. Rev Infect Dis 1991; 13(1): 34-46.
24. Pittet D, Thievent B, Wenzel RP, Li N, Gurman G, Suter PM. Importance of pre-existing comorbidities for prognosis of septicaemia in critically ill patients. Intensive Care Med 1993; 19(5): 265-72.
25. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273: 117-23.
26. Pizzo PA. Management of fever in patients with cancer and treatment induced neutropenia. N Engl J Med 1993; 328: 1323-32
27. Klastersky J. Empirical therapy for bacterial infections in neutropenic patients. Support Care Cancer 1994; 2: 347-54
28. The GIMEMA Infection Program. Prevention of bacterial infection in neutropenic patients with haematologic malignancies: a randomized, multicentre trial comparing norfloxacin with ciprofloxacin. Ann Intern Med 1991; 115: 7-12.
29. Menichetti F, Martino P, Bucaneve G, the GIMEMA Infection Program. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with haematologic malignancies. Antimicrob Agents Chemother 1994; 38: 2041-6.
30. Menichetti F, Del Favero A. The role of Gram-positive therapy in the neutropenic patient. J Antimicrob Chemother 1991; 27(suppl B): 51-60.
31. Bochud PY, Calandra T, Francioli P. Bacteraemia due to viridans streptococci in neutropenic patients: a review. Am J Med 1994; 97: 256-64.
32. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584-93.
33. Carratalà J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone resistant Escherichia coli bactaeremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995; 20: 557-60
34. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. New EnglJ Med 1994; 330(17): 1240-1.
35. Kreger BE, Craven DE, Carling PC, McCabe WR. Gramnegative bacteraemia. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med 1980; 68: 332-43.
36. Shah PM, Fischer M, Schmidt-Weber H, Stille W. Septikaemische erkankungen bei patienten mit aberwehrschwaeche. Muench Med Wochenschr 1983; 125: 216-18.
37. Warren HS, Danner RL, Munford RS. Anti-endotoxin monoclonal antibodies. N Engl J Med 1992; 326(17): 1153-7.
38. Sanford JP. Guide to antimicrobial therapy. Dallas, Texas: Antibacterial Therapy, Inc., 1995.
39. Wood MJ. Therapy: the clinician's view. J Antimicrob Chemother 1990: 25(suppl C): 99-106.
40. Working Committee of the Infectious Diseases Society of America. J Infect Dis 1990; 161. 381-96.
41. Halls GA. Antimicrobial practice. The management of infections and antibiotic therapy: a European survey. J Antimicrob Chemother 1993; 31: 985-1000.
42. Pittet D, Herwaldt L, Massanari M. The intensive care unit. In Brachmann JV, Bennett PS, eds. Hospital infections. Boston: Little Brown, 1992: 405-39.
43. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia: clinical identification of a low risk subgroup at presentation. Arch Intern Med 1988; 148: 2561-8.
44. Malik, IA, Khan WA, Karim M, Aziz Z, Khan A. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia; results of a prospective randomized trial. Am J Med 1995, 98: 224-31.
45. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10: 316-22.
46. Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991; 115: 849-59.
47. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with, fever and neutropenia. N Engl J Med 1986; 315: 552-8.
48. Rolston KVI, Berkey P, Bodey GP, et al. A comparison of imipenem to ceftaxidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992; 152: 283-91.
49. De Pauw BE, Donnelly JP, Raemaekers JMM, Horrevorts A, Hoogkamp Korstanje JAA. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1995; 36: 185-200.
50. The EORTC International Antimicrobial Therapy Project Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteraemia in cancer patients with granulocytopenia. N Engl J Med 1987; 311: 1692-8.
51. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37: 209-22.
52. Brodgen RN, Peters DH. Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47: 823-54.
53. Pizzo PA. Empirical therapy and prevention of infection in the immunocompromised host. In Mandell GL, Bennert JE, Dolin R, eds. Principles and practices of infectious diseases, 4th edn. New York: Churchill Livingstone, 1995: 2686-696.
54. Doern GV, Brueggemann A, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30 center national surveillance study. Antimicrob Agents Chemother 1996; 40: 1208-13.
55. Klugman KP, Dagan R, the Meropenem Meningitis Study Group. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Antimicrob Agents Chemother 1995; 39: 1140-6.
56. Center for Disease Control. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR 1993; 42 597-9.
57. Bates J, Jordens JZ, Griffiths DT. Farm animals as a putative reservoir for vancomycin-resistant enterococcal infection in man. J Antimicrob Chemother 1994; 34: 507-16.
58. Klare I, Heier H, Claus H, et al. Enterococcus faecium strains with vanA-mediated high-level glycopeptide resistance isolated from animal foodstuffs and fecal samples of humans in the community. Microb Drug Resist 1995; 1: 265-72.
59. Gordts B, van Landuyt H, Ieven M, Vandamme P, Goossens H. Vancomycin-resistant enterococci colonizing the intestinal tracts of hospitalized patients. J Clin Microbiol 1995; 33: 2842-6.
60. Plessis P, Lamy T, Donnio PY, et al. Epidemiologic analysis of glycopeptide-resistant Enterococcus strains in neutropenic patients receiving prolonged vancomycin administration. Eur J Clin Microbiol Infect Dis 1995; 14: 959-63.
61. Goldmann DA, the subcommittee on Prevention and Control of Antimicrobial-Resistant Microorganisms in Hospitals. Recommendations for preventing the spread of vancomycin resistance - Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 1995; 44: 1-13.
62. Karanfil LV, Murphy M, Josephson A, et al. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 1992; 13: 195-200.
63. Handwerger S, Raucher B, Altarac D, et al. Nosocomial outbreak due to Enterococcus faectum highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993; 16: 750-5.
64. Frieden TR, Munsiff SS, Low DE. Emergence of vancomycin-resistant enterococci in New York City. Lancet 1995; 342: 76-9.
65. Boyle JF, Soumakis SA, Rendo A, et al. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol 1993; 31: 1280-5.
66. Livornese LL Jr, Dias S, Samel C, et al. Hospital-acquired infection with vancomycin-resistant Enterococcas faecium transmitted by electronic thermometers Ann Intern Med 1992; 117: 112-16.
67. Quale J, Landman D, Atwood E, et al. Experience with a hospital-wide outbreak of vancomycin-resistant enterococci. Am J Infect Control 1996; 24: 372-9.
68. Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995; 20: 1126-33.
69. Jordens JZ, Bates J, Griffiths DT. Faecal carriage and nosocomial spread of vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1994; 34: 515-28.